Evidence map›Paper›PMID 41495872›Full record

ReviewJournal of cardiovascular imaging2026

Multimodality imaging in hypertrophic cardiomyopathy.

Jihoon Kim, Sang-Chol Lee

Erratum issuedAbstract readReview
In one paragraph

Review in Journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Jihoon KimDivision of Cardiology, Department of Internal Medicine, Heart Stroke Vascular Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Sang-Chol LeeDivision of Cardiology, Department of Internal Medicine, Heart Stroke Vascular Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. chrislee.echo@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by unexplained myocardial hypertrophy. Although the diagnosis of HCM is traditionally based on increased left ventricular (LV) wall thickness, contemporary management requires a comprehensive multimodality imaging approach to accurately define disease phenotype, assess functional consequences, and guide risk stratification. Transthoracic echocardiography remains the first-line imaging modality, providing real-time evaluation of LV morphology, systolic and diastolic function, and LV outflow tract obstruction (LVOTO). However, its ability to assess myocardial tissue characteristics and complex morphologic variants may be limited in selected patients. Cardiac magnetic resonance (CMR) offers superior spatial resolution and allows detection of myocardial fibrosis using late gadolinium enhancement. Cardiac computed tomography serves as a complementary tool for evaluating coronary artery anatomy and detailed cardiac structure, particularly in patients with suboptimal echocardiographic windows or contraindications to CMR. This review summarizes the strengths and limitations of each imaging modality and highlights their complementary roles in the evaluation of cardiac morphology, systolic and diastolic function, LVOTO, and tissue characterization. An integrated imaging strategy is essential for optimized diagnosis, individualized risk stratification, and informed therapeutic decision-making in patients with HCM.

Indexed as

Computed tomographyHypertrophic cardiomyopathyImagingMagnetic resonance imaging

Identifiers

PMID41495872
PMCPMC12776975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.